Frontiers in Oncology | |
Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report | |
Oncology | |
Yuxian Liang1  Jiayu Zheng1  Qingyun Pan1  Quanfang Chen1  Lingxin Yan1  Pengli Yu2  | |
[1] Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China;Geneplus-Beijing Institute, Beijing, China; | |
关键词: PPFIA1-ALK; alectinib; NSCLC; NGS; non-reciprocal fusion; | |
DOI : 10.3389/fonc.2023.1264820 | |
received in 2023-07-21, accepted in 2023-08-08, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
Non-small cell lung cancers (NSCLCs) with anaplastic lymphoma kinase (ALK)-rearrangement have favorable responses to ALK inhibitors. However, ALK fusion mutations harbored approximately 90 distinct fusion partners. Patients with different ALK fusions might respond distinctly to different-generation ALK inhibitors. In this case report, we identified a novel non-reciprocal ALK fusion, ALK-C2orf91(intergenic) (A19: intergenic) and PPFIA1-ALK (P2:A20), by next-generation DNA sequencing in an advanced lung adenocarcinoma patient. After 2 months of alectinib, the targeted lung lesion regressed significantly, and evaluation of therapeutic efficiency indicated partial response. To date, the patient had achieved 12 months of progression-free survival from alectinib treatment. Our study extended the spectrum of ALK fusion partners in ALK-positive NSCLC, and we reported a new ALK fusion, PPFIA1-ALK and ALK-C2orf91(intergenic), and its sensitivity to alectinib firstly in lung cancer. We believe that this case report has an important clinical reference.
【 授权许可】
Unknown
Copyright © 2023 Yan, Zheng, Pan, Liang, Yu and Chen
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310100477897ZK.pdf | 5423KB | download |